LONDON, Dec. 18, 2016 /PRNewswire/ --
The Intragastric Balloons are used for weight loss. They are saline-filled silicone balloons placed in the stomach for a span of months and limit the intake of food by giving the feeling of satiety. The Intragastric balloons market in Europe, Middle East, and Africa (EMEA) was valued at $85.81 million in 2017 and is expected to reach $131.71 million by 2023, growing at a CAGR of 6.31% during the forecast period.
Factors such as presence of a large obese population, change in lifestyle, reduced hospital stay, short recovery time, and availability of low-priced Intragastric balloons is driving the growth of the market. However, limitations and adverse events of Intragastric balloons are likely to limit the adoption of this technology.
The Gulf countries have a very high rate of obesity. In Europe, Hungary and the UK top the list of obesity. EMEA is expected to dominate the Intragastric balloons market in the near future. The Intragastric Balloons market was valued at US$136.64 million in 2017 and is expected to reach US$215.92 million by 2023 growing at a CAGR of 6.75% during the forecast period 2017-2023.
The Intragastric balloons market is highly competitive with presence of large, medium, and small players. Some of the major players in this market are Apollo Endoscopy Inc., Spatz FGIA Inc., Allurion Technologies Inc., ReShape Medical Inc., Hélioscopie SA, and Obalon Therapeutics Inc.
Download the full report: https://www.reportbuyer.com/product/4379304/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emea-intragastric-balloons-market-forecast-2017-2023-300380646.html